Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 4.46

(-0.54%)

Net Income Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual net income in 2024 was -62.25 Million USD , up 34.23% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly net income in 2024 FY was -62.25 Million USD , up 34.23% from previous quarter.
Xeris Biopharma Holdings, Inc. reported an annual net income of -94.66 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported an annual net income of -94.66 Million USD in 2022, up 22.87% from previous year.
Xeris Biopharma Holdings, Inc. reported a quarterly net income of -62.25 Million USD for 2024 FY, up 34.23% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a quarterly net income of -18.98 Million USD for 2024 Q3, down -41.75% from previous quarter.

Annual Net Income Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Net Income of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Net Income	Net Income Growth
2024	-62.25 Million USD	34.23%
2023	-94.66 Million USD	0.0%
2022	-94.66 Million USD	22.87%
2021	-122.72 Million USD	-34.66%
2020	-91.14 Million USD	-51.7%
2019	-60.08 Million USD	-126.26%
2018	-26.55 Million USD	-101.03%
2017	-13.2 Million USD	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-12.18 Million USD	38.57%
2024 FY	-62.25 Million USD	34.23%
2024 Q3	-18.98 Million USD	-41.75%
2024 Q4	-15 Million USD	20.94%
2024 Q2	-13.39 Million USD	-9.85%
2023 FY	-94.66 Million USD	0.0%
2023 Q4	-19.84 Million USD	-17.87%
2023 Q3	-16.83 Million USD	15.16%
2023 Q2	-19.84 Million USD	9.11%
2023 Q1	-21.83 Million USD	16.63%
2022 Q2	-50.79 Million USD	-95.28%
2022 Q1	-26 Million USD	5.47%
2022 FY	-94.66 Million USD	22.87%
2022 Q4	-26.18 Million USD	22.33%
2022 Q3	-33.71 Million USD	33.62%
2021 Q3	-18.41 Million USD	15.77%
2021 Q2	-21.85 Million USD	-36.61%
2021 FY	-122.72 Million USD	-34.66%
2021 Q1	-16 Million USD	33.61%
2021 Q4	-27.51 Million USD	-49.45%
2020 FY	-91.14 Million USD	-51.7%
2020 Q1	-32.83 Million USD	4.5%
2020 Q4	-24.09 Million USD	17.42%
2020 Q3	-29.18 Million USD	11.78%
2020 Q2	-33.08 Million USD	-0.75%
2019 Q2	-20.41 Million USD	-38.27%
2019 Q4	-34.38 Million USD	-36.03%
2019 FY	-60.08 Million USD	-126.26%
2019 Q1	-14.76 Million USD	-13.71%
2019 Q3	-25.27 Million USD	-23.79%
2018 Q2	-9.14 Million USD	-21.51%
2018 FY	-26.55 Million USD	-101.03%
2018 Q4	-12.98 Million USD	-9.07%
2018 Q3	-11.9 Million USD	-30.19%
2018 Q1	-7.52 Million USD	-43.86%
2017 Q3	-4.64 Million USD	0.0%
2017 Q4	-5.23 Million USD	-12.54%
2017 FY	-13.2 Million USD	0.0%

Peer Net Income Comparison of Xeris Biopharma Holdings, Inc.

Name	Net Income	Net Income Difference
Arrowhead Pharmaceuticals, Inc.	-205.27 Million USD	69.672%
Codexis, Inc.	-76.24 Million USD	18.343%
Viridian Therapeutics, Inc.	-237.73 Million USD	73.813%
Organovo Holdings, Inc.	-14.67 Million USD	-324.341%